Adverum Biotechnologies, Inc. (ADVM)
| Market Cap | 103.05M |
| Revenue (ttm) | 3.60M |
| Net Income (ttm) | -126.19M |
| Shares Out | 101.03M |
| EPS (ttm) | -1.26 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 579,174 |
| Open | 0.92 |
| Previous Close | 0.92 |
| Day's Range | 0.87 - 1.03 |
| 52-Week Range | 0.53 - 2.34 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 3.50 (+246.54%) |
| Earnings Date | Nov 9, 2023 |
About ADVM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for ADVM stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 246.54% from the latest price.
News
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
REDWOOD CITY, Calif., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Adverum Biotechnologies to Participate in the Evercore ISI 6th Annual HealthCONx Conference
REDWOOD CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Adverum Biotechnologies Reports Third Quarter 2023 Financial Results and Pipeline Highlights
- Announced preliminary aflibercept protein levels from the on-going Phase 2 LUNA trial, suggesting that both doses are within the therapeutically active range and consistent with aflibercept levels o...
Adverum Biotechnologies Appoints C. David Nicholson, Ph.D.
REDWOOD CITY, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Adverum Biotechnologies Announces 3-Year Efficacy and Safety Results from the OPTIC Extension Study in Patients with Wet AMD at AAO 2023
- Patients in OPTIC continue to experience long-term benefit from Ixo-vec through 3 years of follow-up, including maintenance of vision, durability of anatomical improvements and sustained reduction i...
Adverum Biotechnologies Announces Positive Aflibercept Protein Level Data from the LUNA Phase 2 Trial
- Initial aflibercept protein levels in LUNA suggest Ixo-vec at both the 2E11 and 6E10 doses delivers aflibercept protein levels within the therapeutically active range -
Adverum Biotechnologies to Participate in Upcoming Investor Conferences
REDWOOD CITY, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
Adverum Biotechnologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
REDWOOD CITY, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
Adverum Biotechnologies Appoints Andrew Ramelmeier, Ph.D. as Chief Technology Officer
Dr. Ramelmeier has more than 30 years of experience in drug development and clinical and commercial chemistry, manufacturing and controls (CMC), including gene and cell therapies Dr. Ramelmeier has mo...
Adverum Biotechnologies to Participate in the H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
REDWOOD CITY, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Adverum Biotechnologies Completes Enrollment of Phase 2 LUNA Trial in Wet AMD and Reports Second Quarter 2023 Financial Results
- LUNA 14-week data on aflibercept protein levels anticipated in the third quarter of 2023 and preliminary efficacy and safety data anticipated in the fourth quarter of 2023 -
Adverum Biotechnologies Grants License to Ray Therapeutics Inc. for the AAV.7m8 Intravitreal Capsid
Adverum has granted Ray Therapeutics a non-exclusive, royalty-bearing license for the use of Adverum's proprietary intravitreal AAV.7m8 vector capsid together with RayTx's RTx-015 asset Adverum has gr...
Adverum Biotechnologies to Participate in the Jefferies Healthcare Conference
REDWOOD CITY, Calif., June 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Adverum Biotechnologies Announces New Executive Leadership Roles
- Richard Beckman, M.D., chief medical officer, transitions to senior medical advisor - - Star Seyedkazemi, Pharm.D.
Adverum Biotechnologies Presents Nonclinical Data in Support of Ixo-vec's Phase 2 Clinical Development at ASGCT 2023 Annual Meeting
REDWOOD CITY, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly p...
Adverum Biotechnologies Introduces an Intravitreal Gene Therapy Program for Geographic Atrophy and Presents Data on Its Ocular Gene Therapy Platform
- Geographic atrophy (GA) program introduced with complement Factor I (CFI), a key component of the complement cascade, as a payload and utilizing two intravitreal (IVT) capsids, 7m8 and LSV1 -
Adverum Biotechnologies Reports First Quarter 2023 Financial Results
- Full enrollment of the Phase 2 LUNA trial in wet age-related macular degeneration (wet AMD) is anticipated in the second half of 2023 -
Adverum Biotechnologies to Participate in RBC Capital Markets Global Healthcare Conference
REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly p...
Adverum Biotechnologies Announces Upcoming Data Presentations at ASGCT 2023 including Data on a New Intravitreal (IVT) Geographic Atrophy Secondary to Dry AMD
REDWOOD CITY, Calif., May 02, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly p...
Adverum Biotechnologies Presents Nonclinical Data at the 2023 ARVO Annual Meeting Supporting Potential for Staggered Bilateral Administration of Ixo-vec
- Wet age-related macular degeneration (wet AMD) is a bilateral disease and incidence of neovascularization (nAMD) in the second eye is up to 42% in the first two to three years following diagnosis in...
Adverum Biotechnologies Granted Innovative Licensing and Access Pathway Designation in the United Kingdom for Ixo-vec for the Treatment of Wet AMD
- Innovative Licensing and Access Pathway designation is intended to accelerate the regulatory review process in the United Kingdom -
Adverum Biotechnologies Announces Upcoming Nonclinical Data Presentation Supporting Staggered Bilateral Administration of Ixoberogene Soroparvovec (Ixo-vec) at the 2023 ARVO Annual Meeting
REDWOOD CITY, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Phase 2 LUNA Trial Update
- Full enrollment of the LUNA trial anticipated in the second half of 2023 -
Adverum Biotechnologies to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
Adverum Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...